Explore
Upload

DocSlides is a free service to upload presentations and documents.

Upload Now

Search Results for 'Ftc Tdf'

Ftc Tdf published presentations and documents on DocSlides.

Elvitegravir-Cobicistat-TAF-FTC in Hepatitis B Coinfection

Elvitegravir-Cobicistat-TAF-FTC in Hepatitis B Coinfection

  • melanie
  • 9 Slides

Study 1249. Elvitegravir-Cobicistat-TAF-FTC in HIV...

Elvitegravir-Cobicistat-TAF-FTC in Renal Impairment

Elvitegravir-Cobicistat-TAF-FTC in Renal Impairment

  • carl
  • 10 Slides

Study 112. Elvitegravir-Cobicistat-TAF-FTC in Rena...

Switch

Switch

  • lindy-dunigan
  • 13 Slides

from. TDF to TAF. GS-US-292-0109 Study. GS-US-31...

1 Adam O’Neill Leonid

1 Adam O’Neill Leonid

  • celsa-spraggs
  • 137 Slides

Reyzin. Boston University. . A Unified Approach ...

Comparison of NRTI combinations

Comparison of NRTI combinations

  • tawny-fly
  • 20 Slides

ZDV/3TC . vs. TDF + FTC. Study 934. ABC/3TC . vs...

HBV resistance and

HBV resistance and

  • calandra-battersby
  • 21 Slides

immune escape . mutants. Anders Boyd, MPH, . PhD....

Switch to DRV/r + RAL

Switch to DRV/r + RAL

  • debby-jeon
  • 5 Slides

SPARE . Study. SPARE Study: switch to DRV/r + RAL...

ID Week Review 2015

ID Week Review 2015

  • briana-ranney
  • 17 Slides

Brian R. Wood, MD. Assistant Professor of Medicin...

Tyre Stewardship in Canada

Tyre Stewardship in Canada

  • sherrill-nordquist
  • 0 Slides

Presented to . New Zealand . Tyre. Industry Summ...

Comparative effectiveness of first-line antiretroviral therapy regimens: results from a large real-

Comparative effectiveness of first-line antiretroviral therapy regimens: results from a large real-

  • min-jolicoeur
  • 0 Slides

implementation of Dolutegravir. Meireles MV. , Pa...

ACTHIV 2018: A State-of-the-Science Conference for Frontline Health Professionals

ACTHIV 2018: A State-of-the-Science Conference for Frontline Health Professionals

  • phoebe-click
  • 0 Slides

ACTIVITY CODE . TD342. Antiretroviral Medications...

Common Pharmacomistakes in Advanced Illness

Common Pharmacomistakes in Advanced Illness

  • tawny-fly
  • 42 Slides

Common Pharmacomistakes in Advanced Illness Opioi...

Use of HCV DAAs with HIV Regimens

Use of HCV DAAs with HIV Regimens

  • robaut
  • 13 Slides

Sam Lam, . PharmD. Annie Vong, . PharmD. 2/3/2017....

Evolving Options for HBV Therapy:

Evolving Options for HBV Therapy:

  • desiron
  • 39 Slides

Navigating the New Treatment Landscape. Outline. I...

Phase 2 of new ARVs Fostemsavir

Phase 2 of new ARVs Fostemsavir

  • sportyinds
  • 10 Slides

, . prodrug. of . temsavir. . (. attachment inhi...

WHO ARV Forecasting Meeting

WHO ARV Forecasting Meeting

  • sistertive
  • 31 Slides

Geneva, March 19 - 20 , 2015 1 | Treatment and C...

Target Date Funds and P

Target Date Funds and P

  • unita
  • 12 Slides

lan . S. ponsor Responsibilities. Marcia S. Wagner...

Brad Hare Nothing to Disclose

Brad Hare Nothing to Disclose

  • beatrice
  • 17 Slides

Kaiser Permanente San Francisco Medical Center. Sa...

Renal and Bone Safety of

Renal and Bone Safety of

  • ashley
  • 16 Slides

Tenofovir. . Alafenamide. . vs. . Tenofovir. ....

Total Soluble and Insoluble Dietary Fibre Contents of Wild Growing E

Total Soluble and Insoluble Dietary Fibre Contents of Wild Growing E

  • alyssa
  • 7 Slides

302 Vol. 32, 2014, No. 3: 302–307Czech J. Fo...

Retirement Plan Consulting

Retirement Plan Consulting

  • oconnor
  • 30 Slides

Overview of Services. Table of Contents. About RPA...

Subjects with Renal Impairment Switching from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide Have Improved Renal and Bone Safety through 48 Weeks Study GS-US-292-0112

Subjects with Renal Impairment Switching from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide Have Improved Renal and Bone Safety through 48 Weeks Study GS-US-292-0112

  • micah
  • 16 Slides

Tenofovir. . Disoproxil. . Fumarate. to . Tenof...

Raltegravir plus Ritonavir-Boosted Darunavir NEAT001/ANRS 143 Trial

Raltegravir plus Ritonavir-Boosted Darunavir NEAT001/ANRS 143 Trial

  • matthew167
  • 11 Slides

NEAT001/ANRS 143 Trial. Darunavir/r + Raltegravir ...

Innovative Strategies for the Management

Innovative Strategies for the Management

  • karlyn-bohler
  • 37 Slides

of HIV Infection. Dual therapies without NRTIs. J...

CROI 2015: HIV Prevention Updates

CROI 2015: HIV Prevention Updates

  • pamella-moone
  • 24 Slides

Ruanne V Barnabas, . MBChB. . Dphil. Global Heal...

Switch to ATV/

Switch to ATV/

  • cheryl-pisano
  • 16 Slides

r. + RAL. HARNESS Study. ATV/. r. 300/100 mg ....

ID Week 2016: HIV Update

ID Week 2016: HIV Update

  • min-jolicoeur
  • 25 Slides

Robert Harrington, M.D.. ID Week 2016: HIV Update...

Comparison of INSTI vs INSTI

Comparison of INSTI vs INSTI

  • pamella-moone
  • 7 Slides

QDMRK. SPRING-2. ONCEMRK. ONCEMRK. Design. Object...

PrEP Training for

PrEP Training for

  • tatyana-admore
  • 124 Slides

Providers in Clinical Settings. 2. Welcome!. Plea...

Treatment-Experienced Patients in Resource-Limited Settings

Treatment-Experienced Patients in Resource-Limited Settings

  • pasty-toler
  • 12 Slides

Susan M. Graham . Assistant Professor, Medicine a...

CROI 2015: What’s New in Hepatitis?

CROI 2015: What’s New in Hepatitis?

  • myesha-ticknor
  • 19 Slides

Nina Kim, MD . Associate Professor of Medicine. D...

Review of Non-Daily PrEP Clinical Research and Experience

Review of Non-Daily PrEP Clinical Research and Experience

  • mitsue-stanley
  • 0 Slides

Robert M. Grant, M.D., M.P.H. .. IAS 2017, July 2...

ART for Prevention… What Happens Next?

ART for Prevention… What Happens Next?

  • briana-ranney
  • 0 Slides

Myron S. Cohen, MD. Yeargan-Bate Eminent Professo...

Characteristics and Oral

Characteristics and Oral

  • lois-ondreau
  • 0 Slides

PrEP. Adherence in the TDF2 Open-Label Extension...

Adaptive non-inferiority

Adaptive non-inferiority

  • cheryl-pisano
  • 0 Slides

margins under observable non-constancy. Brett Han...

ADOLESCENT PrEP STUDIES

ADOLESCENT PrEP STUDIES

  • min-jolicoeur
  • 0 Slides

. . Shorai. . Mukaka. , . MBchB. ...

Second-Generation HIV-1 Maturation Inhibitor BMS-955176: Antiviral Activity and Safety with Atazan

Second-Generation HIV-1 Maturation Inhibitor BMS-955176: Antiviral Activity and Safety with Atazan

  • sherrill-nordquist
  • 0 Slides

± . Ritonavir. Carey Hwang. ,. 1. Dirk Schürma...

The Role of Pre-Exposure Prophylaxis (

The Role of Pre-Exposure Prophylaxis (

  • tatyana-admore
  • 0 Slides

PrEP. ) for the Prevention of HIV. Sarah . Kemink...

Module 1: INTRODUCTION TO ORAL

Module 1: INTRODUCTION TO ORAL

  • pamella-moone
  • 0 Slides

PrEP. Version. : December . 2018. Outline of tra...

Essentials for Optimal Care of HIV Patients

Essentials for Optimal Care of HIV Patients

  • marina-yarberry
  • 0 Slides

Evidence-Based Approaches. Simply Speaking. ®. ...

Copyright © 2024 DocSlides. All Rights Reserved